15.52 USD
-0.08
0.51%
At close Jan 17, 4:00 PM EST
After hours
15.31
-0.21
1.35%
1 day
-0.51%
5 days
-1.59%
1 month
-16.51%
3 months
-13.30%
6 months
-20.37%
Year to date
-10.24%
1 year
-71.89%
5 years
-86.57%
10 years
-50.82%
 

About: Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.

Employees: 634

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

120% more call options, than puts

Call options by funds: $11.1M | Put options by funds: $5.04M

11% less funds holding

Funds holding: 157 [Q2] → 140 (-17) [Q3]

14.36% less ownership

Funds ownership: 98.64% [Q2] → 84.29% (-14.36%) [Q3]

25% less capital invested

Capital invested by funds: $235M [Q2] → $177M (-$59M) [Q3]

37% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 38

46% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 54

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$17
10%
upside
Avg. target
$17
10%
upside
High target
$17
10%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
DA Davidson
Linda Bolton Weiser
38% 1-year accuracy
39 / 104 met price target
10%upside
$17
Neutral
Upgraded
5 Nov 2024

Financial journalist opinion

Neutral
Zacks Investment Research
1 week ago
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
Neutral
Business Wire
1 week ago
Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND™ For GLP-1 Users & Those Looking for Help to Keep Weight Off
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE:MED), the health and wellness company known for its habit based and coach-guided lifestyle solution OPTAVIA, today announced OPTAVIA ASCEND — a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle hea.
Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND™ For GLP-1 Users & Those Looking for Help to Keep Weight Off
Neutral
Business Wire
1 month ago
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessar.
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications
Positive
Zacks Investment Research
2 months ago
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
Positive
Zacks Investment Research
2 months ago
Are Investors Undervaluing MEDIFAST (MED) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing MEDIFAST (MED) Right Now?
Positive
Seeking Alpha
2 months ago
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share.
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Negative
Zacks Investment Research
2 months ago
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
Positive
Zacks Investment Research
2 months ago
Medifast (MED) Beats Q3 Earnings and Revenue Estimates
Medifast (MED) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $2.12 per share a year ago.
Medifast (MED) Beats Q3 Earnings and Revenue Estimates
Neutral
Seeking Alpha
2 months ago
Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President-Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Jim Salera - Stephens Inc. Linda Bolton-Weiser - D.A. Davidson Operator Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call.
Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
2 months ago
Medifast Announces Third Quarter 2024 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted.
Medifast Announces Third Quarter 2024 Financial Results
Charts implemented using Lightweight Charts™